Business News (Licences, Deals)
01-05-2009 |
18:03 hs.
U.S. drugmaker Pfizer has agreed to pay up to $140 million dollars for Cytos Biotechnology Ltd. world-wide exclusive rights to market vaccines, based on Cytos biotech Immunodrug Technology.
12-30-2008 |
07:57 hs.
Eli Lilly signed a licensing agreement with Canadian biotech BioMS, to develop an market the experimental drug Dirucotide, to treat advanced forms of multiple sclerosis. The deal was closed for $497 million dollars.
Up to $1.4B
12-23-2008 |
12:27 hs.
GlaxoSmithkline Plc secured a multimillion dollar deal with Archemix to develop and market aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
12-17-2008 |
10:38 hs.
GlaxoSmithKline Plc and Dynavax Technologies Corp. signed a deal to develop first-in-class endosomal TLR inhibitors for autoimmune and inflammatory diseases.
12-10-2008 |
18:44 hs.
According to Reuters, MediGene received offers from Pfizer and Eli Lilly & Co. for marketing rights to EndoTAG, a treatment for pancreatic cancer. Roche Holding AG and Amgen are reportedly expected to bid before the year ends.
11-25-2008 |
16:44 hs.
Anglo-Swedish drugmaker Astra Zeneca Plc said it was ready to end a two year deal with U.S.based Abraxis BioScience Inc. for the co-promotion of breast cancer drug Abraxane.
11-24-2008 |
15:33 hs.
$ 4.2 B deal goes through
11-07-2008 |
09:50 hs.
Japan´s Daiichi Sankyo Co announced it had completed the takeover of India´s Ranbaxy Laboratories Ltd, buying a 63.9 percent stake for 199.8 billion Indian rupees ($ 4.2 billion dollars).
Worth about $ 673 M
11-05-2008 |
10:26 hs.
Europe´s third-largest oil company, Total SA, sold shares in drugmaker Sanofi-Aventis totaling some $ 673 million dollars this past third-quarter. Total owns 12.7 percent of Sanofi.
$ 57 M deal includes hepatitis C pipeline
10-30-2008 |
09:42 hs.
GlaxoSmithKline announced it has launched a tender offer for California-based Genelabs Technologies Inc. for approximately $ 57 million dollars.
$ 115 million-dollar deal
10-21-2008 |
09:10 hs.
Novartis AG has reached a deal to buy part of the pulmonary drug delivery business of Nektar Therapeutics for $ 115 million dollars in cash. Nektar retains ownership of its pipeline program partnered with Bayer.
Epilepsy treatment
10-20-2008 |
10:40 hs.
Optimization platform
10-20-2008 |
10:32 hs.
U.S.´s Pfizer Inc and Belgian drug maker UCB have formed a joint venture company called Cyclofluidic, with investment from the British government, to develop technologies that automate and speed up the drug development process.
Cilomilast, under development
10-15-2008 |
12:19 hs.
Eye care company Alcon Inc reported it expanded a licensing agreement with GlaxoSmithKline for global ophthalmic rights to compound cilomilast.
$ 3 M deal, plus milestone, royalty payments
10-08-2008 |
12:52 hs.
Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975 (formerly IPH 2101) in exchange for a $ 3 million dollar upfront payment, milestone payments and royalties on future sales of the drug.
10-08-2008 |
12:28 hs.
Shareholders to receive $ 70-per-share
10-06-2008 |
09:53 hs.
Eli Lilly & Co has agreed to acquire ImClone Systems Inc for $ 70-per share, in a deal amounting to some $ 6.5 billion dollars, it was announced by the two companies. This leaves far behind ImClone Systems´ Erbitux-marketing partner Bristol-Myers Squibb´s offer of $ 62-per-share made in September.
10-03-2008 |
10:26 hs.
The notification to EU competition regulators of plans by France´s Sanofi-Aventis to buy Czech generic drugmaker Zentiva is incomplete, the European Commission said. Sanofi says the deadline of the bid will not change.
Acquisition valued at $ 4.6 B
10-03-2008 |
10:09 hs.
Daiichi Sankyo´s bid to acquire the Ranbaxy founding family´s stake in the generics company has been approved by the Indian government, it was announced by Finance Minister Palaniappan Chidambaram. The sale will be worth some $ 4.6 billion dollars.
WSJ on track
10-02-2008 |
10:05 hs.
Without any confirmation from ImClone CEO Carl Icahn as yet, the mystery pharmaceutical ‘romancing’ ImClone Systems Inc is likely Eli Lilly & Co, according to the Wall Street Journal, citing an unidentified source. Icahn stated a large drugmaker has completed due diligence, and is continuing to negotiate a formal proposal to buy the biotechnology company at $ 70 per share. Further details.
